(A)
(B)
Group M.S. O.S. Mean
TMZ 26 29 25.7
MSC/CD 18 23 19.4
TMZ + MSC/CD 25 30 26
S1. Efficacy of MSC/CD with TMZ in syngeneic glioma model:
(A) Schematic diagram to evaluate antitumor effect of MSC/CD + TMZ in syngeneic mice GL261/GFP glioma cells and MSC/CD cells were transplanted with 3x104 cells and administrated 5-FC and TMZ at indicated time points with 1000 mg/kg/day P.O. of 5-FC and 5 mg/kg/day of TMZ in C57BL/6 mice, respectively. (B) The Kaplan-Meier graph indicated that the survival of mice (n=8).
34 REFERENCES
Aboody K, Najbauer J and Danks M: Stem and progenitor cell-mediated tumor selective gene therapy. Gene therapy 15: 739-752, 2008
Aboody KS, Najbauer J, Schmidt NO, Yang W, Wu JK, Zhuge Y, Przylecki W, Carroll R, Black PM and Perides G: Targeting of melanoma brain metastases using engineered neural stem/progenitor cells. Neuro-oncology 8:
119-126, 2006
Ahmed AU, Tyler MA, Thaci B, Alexiades NG, Han Y, Ulasov IV and Lesniak MS: A comparative study of neural and mesenchymal stem cell-based carriers for oncolytic adenovirus in a model of malignant glioma. Molecular pharmaceutics 8: 1559, 2011
Alvarez RD, Gomez-Navarro J, Wang M, Barnes MN, Strong TV, Arani RB, Arafat W, Hughes JV, Siegal GP and Curiel DT: Adenoviral-mediated suicide gene therapy for ovarian cancer. Molecular therapy 2: 524-530, 2000
Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, Mignot G, Maiuri MC, Ullrich E and Saulnier P: Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nature medicine 13: 1050-1059, 2007
Bracci L, Schiavoni G, Sistigu A and Belardelli F: Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. Cell Death & Differentiation 21:
15-25, 2014
Chang DY, Yoo SW, Hong Y, Kim S, Kim SJ, Yoon SH, Cho KG, Paek SH, Lee YD and Kim SS: The growth of brain tumors can be suppressed by multiple transplantation of mesenchymal stem cells expressing cytosine deaminase. International journal of cancer 127: 1975-1983, 2010
Damia G and D’Incalci M (1998). Mechanisms of resistance to alkylating agents.
Multiple Drug Resistance in Cancer 2, Springer: 165-173.
35
Danks MK, Yoon KJ, Bush RA, Remack JS, Wierdl M, Tsurkan L, Kim SU, Garcia E, Metz MZ and Najbauer J: Tumor-targeted enzyme/prodrug therapy mediates long-term disease-free survival of mice bearing disseminated neuroblastoma. Cancer research 67: 22-25, 2007
Escott EJ and Rubinstein D: Free DICOM Image Viewing and Processing Software for Your Desktop Computer: What’s Available and What It Can Do for You 1. Radiographics 23: 1341-1357, 2003
Frank RT, Najbauer J and Aboody KS: Concise review: stem cells as an emerging platform for antibody therapy of cancer. Stem Cells 28: 2084-2087, 2010
Ghiringhelli F and Apetoh L: Chemotherapy and immunomodulation: from immunogenic chemotherapies to novel therapeutic strategies. Future Oncology 9: 469-472, 2013
Gutova M, Shackleford GM, Khankaldyyan V, Herrmann KA, Shi X-H, Mittelholtz K, Abramyants Y, Blanchard MS, Kim SU and Annala AJ: Neural stem cell-mediated CE/CPT-11 enzyme/prodrug therapy in transgenic mouse model of intracerebellar medulloblastoma. Gene therapy 20: 143-150, 2013
Hegi ME, Diserens A-C, Gorlia T, Hamou M-F, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W and Mariani L: MGMT gene silencing and benefit from temozolomide in glioblastoma. New England Journal of Medicine 352: 997-1003, 2005
Hiraoka K, Inagaki A, Kato Y, Huang TT, Mitchell LA, Kamijima S, Takahashi M, Matsumoto H, Hacke K and Kruse CA: Retroviral replicating vector-mediated gene therapy achieves long-term control of tumor recurrence and leads to durable anticancer immunity. Neuro-oncology 2017
Imitola J, Raddassi K, Park KI, Mueller F-J, Nieto M, Teng YD, Frenkel D, Li J, Sidman RL and Walsh CA: Directed migration of neural stem cells to sites of CNS injury by the stromal cell-derived factor 1α/CXC chemokine receptor 4 pathway. Proceedings of the National Academy of Sciences 101:
18117-18122, 2004
36
Immonen A, Vapalahti M, Tyynelä K, Hurskainen H, Sandmair A, Vanninen R, Langford G, Murray N and Ylä-Herttuala S: AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study. Molecular therapy 10: 967-972, 2004
Kendall SE, Najbauer J, Johnston HF, Metz MZ, Li S, Bowers M, Garcia E, Kim SU, Barish ME and Aboody KS: Neural Stem Cell Targeting of Glioma Is Dependent on Phosphoinositide 3‐ Kinase Signaling. Stem cells 26: 1575-1586, 2008
Kim SM, Lim JY, Park SI, Jeong CH, Oh JH, Jeong M, Oh W, Park S-H, Sung Y-C and Jeun S-S: Gene therapy using TRAIL-secreting human umbilical cord blood–derived mesenchymal stem cells against intracranial glioma.
Cancer research 68: 9614-9623, 2008
Kuratsu J-i, Yoshizato K, Yoshimura T, Leonard EJ, Takeshima H and Ushio Y: Quantitative study of monocyte chemoattractant protein-1 (MCP-1) in cerebrospinal fluid and cyst fluid from patients with malignant glioma.
Journal of the National Cancer Institute 85: 1836-1839, 1993
Logg CR, Robbins JM, Jolly DJ, Gruber HE and Kasahara N: Retroviral replicating vectors in cancer. Methods Enzymol 507: 199-228, 2012
Longley DB, Harkin DP and Johnston PG: 5-fluorouracil: mechanisms of action and clinical strategies. Nature Reviews Cancer 3: 330-338, 2003
Malhi H and Gores GJ: TRAIL resistance results in cancer progression: a TRAIL to perdition? Oncogene 25: 7333-7335, 2006
Nagasawa DT, Chow F, Yew A, Kim W, Cremer N and Yang I:
Temozolomide and other potential agents for the treatment of glioblastoma multiforme. Neurosurgery clinics of North America 23: 307-322, 2012
Nakamizo A, Marini F, Amano T, Khan A, Studeny M, Gumin J, Chen J, Hentschel S, Vecil G and Dembinski J: Human bone marrow–derived
37
mesenchymal stem cells in the treatment of gliomas. Cancer research 65:
3307-3318, 2005
Nakamura K, Ito Y, Kawano Y, Kurozumi K, Kobune M, Tsuda H, Bizen A, Honmou O, Niitsu Y and Hamada H: Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model. Gene therapy 11:
1155-1164, 2004
Nasu Y, Saika T, Ebara S, Kusaka N, Kaku H, Abarzua F, Manabe D, Thompson TC and Kumon H: Suicide gene therapy with adenoviral delivery of HSV-tK gene for patients with local recurrence of prostate cancer after hormonal therapy. Molecular Therapy 15: 834-840, 2007
Ohtsu A, Baba H, Sakata Y, Mitachi Y, Horikoshi N, Sugimachi K, Taguchi T and Group S-CCCS: Phase II study of S-1, a novel oral fluoropyrimidine derivative, in patients with metastatic colorectal carcinoma. British journal of cancer 83: 141, 2000
Perez-Diez A, Joncker NT, Choi K, Chan WF, Anderson CC, Lantz O and Matzinger P: CD4 cells can be more efficient at tumor rejection than CD8 cells.
Blood 109: 5346-5354, 2007
Portsmouth D, Hlavaty J and Renner M: Suicide genes for cancer therapy.
Molecular aspects of medicine 28: 4-41, 2007
Seol HJ, Jin J, Seong D-H, Joo KM, Kang W, Yang H, Kim J, Shin CS, Kim Y and Kim KH: Genetically engineered human neural stem cells with rabbit carboxyl esterase can target brain metastasis from breast cancer. Cancer letters 311: 152-159, 2011
Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B and Belanger K: Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. The lancet oncology 10: 459-466, 2009
38
Stupp R, Hegi ME, van den Bent MJ, Mason WP, Weller M, Mirimanoff RO, Cairncross JG, Research EOf, Tumor ToCB, Groups R and Group NCIoCCT:
Changing paradigms—an update on the multidisciplinary management of malignant glioma. The oncologist 11: 165-180, 2006
Stupp R, Mason WP, Van Den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C and Bogdahn U: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New England Journal of Medicine 352: 987-996, 2005
Watters JJ, Schartner JM and Badie B: Microglia function in brain tumors.
Journal of neuroscience research 81: 447-455, 2005
Zhao L, Wientjes MG and Au JL: Evaluation of combination chemotherapy.
Clinical Cancer Research 10: 7994-8004, 2004